The effects of hypoglycemic drugs (gliclazide, glibenclamide) and new sugar-lowering drug diabenol on the coagulation chain of hemostasis and fibrinolytic system of blood have been studied in intact rats and in rats with experimental diabetes mellitus. Experiments revealed the ability of drugs to reduce thromboelastogram indices, which is probably related to the ability of hypoglycemic drugs to inhibit the platelet aggregation and prevent the subsequent activation of the coagulation chain of hemostasis. All drugs improve the thrombogenic potential (by decreasing the platelet activation) and increase the activity of the fibrinolytic system of blood. The activity of diabenol and gliclazide i s more pronounced as compared to that of glibenclamide.